Barinthus Biotherapeutics plc (BRNS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Barinthus Biotherapeutics plc (BRNS) has a cash flow conversion efficiency ratio of -0.127x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.73 Million) by net assets ($84.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BRNS defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Barinthus Biotherapeutics plc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Barinthus Biotherapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Barinthus Biotherapeutics plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Barinthus Biotherapeutics plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Slj Global Tbk
JK:SULI
|
-0.018x |
|
Greenyield Bhd
KLSE:0136
|
0.001x |
|
Wulff-Yhtiot Oy
HE:WUF1V
|
0.164x |
|
West High Yield Resources Ltd
V:WHY
|
0.104x |
|
Sufrin Holdings Ltd
TA:SFRN
|
N/A |
|
Eduspec Holdings Bhd
KLSE:0107
|
-0.052x |
|
Neuroone Medical Technologies Corp
NASDAQ:NMTC
|
-0.247x |
|
Chariot Oil & Gas Limited
F:C62
|
-0.033x |
Annual Cash Flow Conversion Efficiency for Barinthus Biotherapeutics plc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Barinthus Biotherapeutics plc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Barinthus Biotherapeutics plc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $130.13 Million | $-28.94 Million | -0.222x | +18.34% |
| 2023-12-31 | $187.00 Million | $-50.92 Million | -0.272x | -358.95% |
| 2022-12-31 | $243.20 Million | $-14.43 Million | -0.059x | +54.01% |
| 2021-12-31 | $252.56 Million | $-32.58 Million | -0.129x | -103.68% |
| 2020-12-31 | $-3.15 Million | $-11.03 Million | 3.504x | +312.44% |
| 2019-12-31 | $-22.08 Million | $-18.76 Million | 0.850x | -- |
About Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targetin… Read more